Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

Senhwa doses first subject in trial of Pidnarulex for solid tumours,

Pidnarulex offered clinically significant and durable benefits in patients with specific tumour biomarkers in a previous Phase I trial. Credit: Arek …, Pidnarulex offered clinically significant and durable benefits in patients with specific tumour biomarkers in a previous Phase I trial. Credit: Arek …, Read More

Scroll to Top